Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kate Milson
Kate Badr
London +44 20 7067 2388 kbadr@cov.com Download V-card

Kate Badr is an associate in the corporate practice group in the London office.

Ms. Badr's practice covers a broad range of transactional and advisory matters, including mergers and acquisitions, corporate restructurings, strategic investments, corporate governance and general corporate and commercial advisory work, with a particular focus on the branded goods and life sciences industries.

  • Redx Pharma plc, an AIM-quoted drug discovery and development company on a placing, subscription and open offer raising approximately £12 million by means of accelerated book build. 
  • AstraZeneca in connection with the divestment of its rights to Rhinocort Aqua outside the U.S.
  • AstraZeneca in connection with the acquisition of Takeda’s Respiratory Business.
  • Oxford BioMedica plc, a bio-pharmaceutical company listed on the London Main Market:
    • a follow-on financing to raise £8.1 million pursuant to a placing of new ordinary shares with both new and existing investors; and
    • on a firm placing, subscription, related party subscription and open offer to raise up to £23.7 million.
  • A global pharmaceutical company in connection with its entry into a drug discovery joint venture with a partner in Japan.
  • Bacardi Limited in relation to the negotiation and implementation of a global working capital syndicated multicurrency loan facility.
  • Silence Therapeutics plc, an AIM-quoted gene therapy company on a placing to raise up to £11.4 million by means of accelerated book build.
  • Giorgio Armani S.p.A. on a joint venture with an Indian property consortium for the import, sale and distribution of Armani branded goods in India.
  • A leading U.S. multinational pharmaceutical company on its international post-merger integration and restructuring programme.
  • A software company in relation to its share reorganisation and its negotiation of a loan facility.

Pro Bono

  • Advising an international charitable organisation that provides micro financing to the world’s lowest-income entrepreneurs on various corporate issues.

Previous Experience

  • Secondment to Microsoft, providing strategic counsel in relation to a full spectrum of commercial, litigious and contentious matters, data protection and intellectual property issues.